Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
复制标题
DOI：
10.1093/ofid/ofy168
复制
发表时间：
2018-07-01
影响因子：
4.2
通讯作者：
Skalweit, Marion J.
中科院分区：
文献类型：
--
作者：
Dousa, Khalid M.;Babiker, Ahmed;Skalweit, Marion J.
伊布替尼是一种不可逆的布鲁顿酪氨酸激酶抑制剂，已批准用于治疗B细胞恶性肿瘤。人们越来越关注伊布替尼治疗后机会性感染的风险。在此，我们描述了第一例龟分枝杆菌皮肤和软组织感染的患者接受伊曲替尼，并叙述了治疗这种感染的挑战。
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.